4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Non-Current Assets data on file, last reported at $107.5 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 41.29% year-over-year to $107.5 million in Q1 2026; TTM through Mar 2026 was $543.1 million, a 15.7% increase from a year earlier, with the FY2025 full-year figure at $153.6 million, up 22.42% from the prior year.
• Non-Current Assets for Q1 2026 stood at $107.5 million, down from $153.6 million in the prior quarter.
• Over the last five years, Non-Current Assets for FDMT reached as high as $183.2 million in Q1 2025 and fell as low as $33.4 million in Q3 2023.
• Historically, Non-Current Assets has averaged $87.2 million across 5 years, with a median of $81.9 million in 2022.
• On a YoY basis, Non-Current Assets climbed as much as 1358.74% in 2022 and fell as far as 57.48% in 2022.
• Year by year, Non-Current Assets stood at $41.3 million in 2022, then gained by 4.76% to $43.3 million in 2023, then soared by 189.71% to $125.5 million in 2024, then increased by 22.42% to $153.6 million in 2025, then declined by 29.98% to $107.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $107.5 million in Q1 2026, $153.6 million in Q4 2025, and $111.6 million in Q3 2025.